

# Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma

NCT06790602

---

Status	RECRUITING
Phase	Phase 2
Sponsor	University of California, San Diego
Enrollment	43 participants

## Plain Language Summary

---

This study is testing whether combining cemiplimab (an immunotherapy drug) with gemcitabine (a chemotherapy drug) can help patients with metastatic pancreatic cancer whose tumors have specific genetic changes in a group of genes called SWI/SNF. These mutations may make tumors more sensitive to immune-based treatments.

**\*\*You may be eligible if...\*\***

- You are 18 years or older
- You have metastatic pancreatic ductal adenocarcinoma (the most common type of pancreatic cancer, which has spread to other parts of the body)
- Your tumor has specific genetic mutations in the SWI/SNF chromatin remodeling complex (such as ARID1A, ARID1B, PBRM1, SMARCA4, or SMARCB1), detected by genetic sequencing
- You have received exactly one prior line of treatment for pancreatic cancer (not immunotherapy or cell therapy)
- You have measurable disease on a scan

**\*\*You may NOT be eligible if...\*\***

- Your tumor does not have SWI/SNF gene mutations
- You have not received any prior treatment, or you have received more than one line of prior therapy
- You have previously received immunotherapy or cell-based therapy
- You do not have measurable disease

Talk to your doctor to see if this trial is right for you.

## Key Eligibility Criteria

---

### Inclusion (15)

- At least 18 years of age.
- Ability to understand the nature of this study, comply with study and follow-up procedures, and give written informed consent.
- Histologically or cytologically confirmed pancreatic ductal adenocarcinoma. Primary tumor can be intact or post-resection with newly developed metastatic disease.
- Stage IV disease (measurable disease by Immunotherapeutics Response Evaluation Criteria in Solid Tumors is required).
- Alterations in SWI/SNF complex chromatin remodeling genes (ARID1A, ARID1B, PBRM1, SMARCA4 and SMARCB1, etc.) detected by next generation sequencing performed prior to enrollment on an ultrasound-guided core biopsy of the primary tumor.
- ... and 10 more (see full listing online)

### Exclusion (19)

- Two or more lines of systemic or previous investigational therapy for metastatic pancreatic ductal adenocarcinoma.
- History of any autoimmune disease requiring treatment within the past 12 months prior to enrollment.
- History of transplanted organ/bone marrow.

- History of interstitial lung disease.
- History of stroke or intracranial hemorrhage within 6 months prior to enrollment.

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).

... and 14 more (see full listing online)

## Locations (1 total)

---

University of California, San Diego, La Jolla, California, United States

---

<https://clinicaltrials.gov/study/NCT06790602>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://ClinicalTrials.gov). Generated by [ClinicalTrialsFinder.org](https://ClinicalTrialsFinder.org).